NCT04703920View on ClinicalTrials.gov

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 4, 2021

Primary Completion Date

December 1, 2024

Study Completion Date

January 2, 2025

Conditions
Metastatic Breast CancerMetastatic Castration-resistant Prostate CancerMetastatic Ovarian CarcinomaMetastic or Unresectable Pancreatic Adenocarcinoma
Interventions
DRUG

Talazoparib

Talazoparib will be administered in increasing doses up to 1 mg orally once a day.

DRUG

Belinostat

Belinostat will be administered in increasing doses up to 1000 mg/m2 IV once daily on days 1-5 of a 21-day cycle.

Trial Locations (1)

48109

University of Michigan Rogel Cancer Center, Ann Arbor

Sponsors
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Acrotech Biopharma Inc.

INDUSTRY

lead

University of Michigan Rogel Cancer Center

OTHER